Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs

VIVIAN P. BYKERK, POONEH AKHAVAN, GLEN S. HAZLEWOOD, ORIT SCHIEIR, ANNE DOOLEY, BOULOS HARAOUI, MAJED KHRAISHI, SHARON A. LECLERCQ, JEAN LÉGARÉ, DIANE P. MOSHER, JAMES PENCHARZ, JANET E. POPE, JOHN THOMSON, CARTER THORNE, MICHEL ZUMMER, and CLAIRE BOMBARDIER

ABSTRACT. Objective. The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part 1 is reported here.

Methods. The CRA Therapeutics Committee assembled a national working group of RA clinical experts, researchers, patient consumers, and a general practitioner. Treatment questions were developed a priori based on results of a national needs assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and the grey literature. Guideline quality was assessed by 2 independent reviewers, and guideline characteristics, recommendations, and supporting evidence from observational studies and randomized controlled trials were synthesized into evidence tables. The full working group reviewed the evidence tables and developed recommendations using a modified Delphi technique.

Results. Five overarching principles and 26 recommendations addressing general RA management strategies and treatment with glucocorticoids and traditional and biologic DMARD were developed for rheumatologists, other primary prescribers of RA drug therapies, and patients with RA.

Conclusion. These recommendations were developed based on a synthesis of international guidelines, supporting evidence, and expert consensus considering the Canadian healthcare context with the intention of promoting best practices and improving healthcare delivery for persons with RA. (First Release Sept 15 2011; J Rheumatol 2012;39:1559–82; doi:10.3899/jrheum.110207)

Key Indexing Terms:
RHEUMATOID ARTHRITIS
CONSENSUS DEVELOPMENT CONFERENCE
QUALITY OF HEALTHCARE
PRACTICE GUIDELINES
DRUG THERAPY

From the Department of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Division of Rheumatology, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Department of Health Policy, Management and Evaluation, University of Toronto; Toronto General Research Institute, University Health Network; Department of Public Health Sciences, University of Toronto; Arthritis Community Research and Evaluation Unit, Toronto Western Research Institute, Toronto, Ontario; Department of Medicine, University of Montreal, Montreal, Quebec; Division of Rheumatology, Memory University of Newfoundland, St. John’s, Newfoundland; Division of Rheumatology, University of Calgary, Calgary, Alberta; Credit Valley Family Health Team, Credit Valley Hospital, Mississauga, Ontario; Division of Rheumatology, University of Western Ontario, London, Ontario; Division of Rheumatology, University of Ottawa, Ottawa, Ontario; The Arthritis Program, Southlake Regional Health Centre, Newmarket, Ontario; Service de Rhumatologie, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; and Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada.

Supported by a Canadian Institutes of Health Research (CIHR) Scoping Reviews and Research Syntheses Grant and matched funds from the Canadian Rheumatology Association (CRA). O. Scheir is supported by a Fonds de la Recherche en Santé de Quebec (FRSQ) Doctoral Research Award. Dr. Akhavan is supported by a UCB/CRA/TAS Post-Graduate Rheumatology Fellowship. Dr. Hazlewood is supported by a UCB/CRA/TAS Post-Graduate Rheumatology Fellowship and an Alberta Heritage Foundation for Medical Research Clinical Fellowship. Dr. Bombardier holds a Pfizer Chair and a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care.

V.P. Bykerk, MD, FRCPC, Assistant Professor, University of Toronto, Instructor, Harvard University, Department of Rheumatology, Mount Sinai Hospital; P. Akhavan, MD, FRCP; G.S. Hazlewood, MD, FRCPC; O. Scheir, MSc; A. Dooley, BA; B. Harouei, MD, FRCP; Clinical Associate Professor of Medicine, University of Montreal; M. Khraishi, MB, BCH, FRCPC, Clinical Professor of Medicine, Memorial University of Newfoundland, Medical Director (Rheumatolog), Nexus Clinical Research; S.A. LeClercq, MD, FRCP; Clinical Associate Professor, Division of Rheumatology, University of Calgary; J. Legaré, Volunteer, Arthritis Patient Advocate; D.P. Mosher, MD, FRCP; Division Chief, Rheumatology, University of Calgary; J. Pencharz, MD, MSc; J.E. Pope, MD, MPH, FRCP; Professor, Schulich School of Medicine and Dentistry, University of Western Ontario; C. Thorne, MD, Director, The Arthritis Program, Southlake Regional Health Centre; J. Thomson, MD, FRCP; Assistant Professor, Department of Medicine, University of Ottawa; M. Zummer, MD, FRCP; Associate Professor, Department of Medicine, University of Montreal, Hôpital Maisonneuve-Rosemont; C. Bombardier, MD, FRCP; Professor, Department of Rheumatology, Mount Sinai Hospital, Department of Health Policy, Management, and Evaluation, University of Toronto, and Division of Clinical Decision Making and Health Care, Toronto General Research Institute, University Health Network.

Bykerk, et al: CRA RA practice recommendations

www.jrheum.orgDownloaded on June 8, 2022 from www.jrheum.org
Recommendations were based on the highest quality of evidence available at the time the working group undertook this review, and are intended to promote best practices and improve healthcare delivery for persons with rheumatoid arthritis (RA). Recommendations, however, should not be interpreted as rigid or legal standards, nor are they meant to replace the clinical judgement of specialists and other trained RA healthcare providers acting according to the individual needs of the patient and the unique clinical circumstance.

Rheumatoid arthritis is a chronic autoimmune disease characterized by inflammation, pain, stiffness, and progressive joint destruction currently affecting about 300,000 Canadians. In addition to higher rates of morbidity and mortality, persons with RA experience significant financial and productivity losses, as well as symptom, emotional and social burdens affecting their health-related quality of life.

The pharmacologic management of RA has progressed substantially over the last decade. Earlier and more aggressive treatment strategies with traditional disease-modifying anti-rheumatic drugs (DMARD) and the more recent introduction of biologic therapies that target specific mechanisms of inflammation have been shown to alter the clinical course of RA and slow or halt radiographic progression. The most commonly prescribed traditional DMARD are methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), and hydroxychloroquine (HCQ).

Biologic therapies currently approved for use in Canada include (1) tumor necrosis factor inhibitors [anti-TNF; etanercept (ETN), infliximab (IFX), adalimumab (ADA), golimumab (GOL), and certolizumab pegol (CTZ)]; (2) T cell costimulatory inhibitor [abatacept (ABAT)]; (3) B lymphocyte-depleting agent [rituximab (RTX)]; (4) interleukin 6 (IL-6) antagonist [tocilizumab (TCZ)]; and (5) IL-1 antagonist (anakinra), although anakinra is used far less often in RA due to side effects and its decreased magnitude of benefit relative to other biologic agents.

Need for Canadian guidance. There are outstanding questions regarding the optimal use of traditional DMARD, and newer biologic therapies, and the international literature regarding the efficacy and potential harms of RA drug therapies continues to grow exponentially. High quality clinical practice guidelines can be a useful knowledge tool to help translate evidence-based healthcare to the appropriate end-users in an accessible and manageable format. There are several published international RA guidelines; however, many individual guidelines have limited scope, and vary in quality and/or timeliness of evidence reviewed. Canadian RA healthcare providers, decision makers, and consumers need guidance that has been developed taking into account the Canadian practice setting.

The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of RA with traditional and biologic DMARD in 2 parts, part 1 providing focused treatment guidance and part 2 providing focused guidance on safety aspects of the pharmacological management of RA.

Objective. The objective was to develop Part 1 of CRA recommendations for the pharmacological treatment of RA with traditional and biologic DMARD based on a synthesis of international guidelines, supporting evidence, and expert consensus of a national Canadian RA working group.

Target patient population. The target population for these recommendations are adult (age ≥ 18 years) patients with RA according to prior and current classification criteria and patients with early inflammatory arthritis suspected of having RA by a trained RA healthcare provider.

Target users. The target users of these recommendations are rheumatologists or other primary prescribers of RA medications who are treating patients with RA in community and academic practice settings and RA patient consumers. Recommendations may also be of interest to other provincial and federal RA stakeholders and decision makers.

What is covered. These recommendations are the first of 2 parts and include 26 recommendations across the following RA treatment domains: general RA management strategies; treatment with glucocorticoids (GC); treatment with traditional DMARD; and treatment with biologic DMARD. Specific key questions are presented in Table 1.

What is not covered. The present document does not include recommendations for nonpharmacological treatments or for other adjunctive therapies for patients with RA, including nonsteroidal antiinflammatory drugs (NSAID). Although costs were embedded in the discussion of each recommendation, a formal cost-effectiveness analysis was not performed. Further, there is a lack of direct comparative effectiveness data for RA drug therapies. Detailed guidance for safety and monitoring of traditional and biologic DMARD is published separately in a second installment of Canadian recommendations.

Funding and conflict of interest. This guidance was funded through the Canadian Institutes of Health Research (CIHR) and matched funds from the Canadian Rheumatology Association (CRA). Potential conflicts for each working group member including industry funding, consultancies, commercial interests, and direct involvement in any guidelines included in the systematic review for the last 3 years are shown in Appendix 1.

Applicability/dissemination strategies. These recommendations were endorsed by the CRA on January 17, 2011, for a period of 2 years. Moreover, Canadian recommendations,
Table 1. Key questions regarding the pharmacological treatment of patients with rheumatoid arthritis (RA).

<table>
<thead>
<tr>
<th>Number</th>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>What are the goals of treatment?</td>
</tr>
<tr>
<td>2</td>
<td>What are poor prognostic features that should be measured at baseline to inform treatment decisions?</td>
</tr>
<tr>
<td>3</td>
<td>How often should disease activity be monitored?</td>
</tr>
<tr>
<td>4</td>
<td>How often should the treatment strategy be adjusted in patients with RA?</td>
</tr>
<tr>
<td>5</td>
<td>How often should radiographs be ordered?</td>
</tr>
<tr>
<td>6</td>
<td>Should therapy be changed in RA patients with adequate clinical response but with unequivocal x-ray progression?</td>
</tr>
</tbody>
</table>

Treatments with glucocorticoids
7. What is the role of glucocorticoids in the management of RA?
8. When should glucocorticoids be used first?
9. Which glucocorticoids should be used to treat RA?
10. Which investigations should be ordered prior to starting treatment with glucocorticoids?
11. What is the optimal dosing strategy for glucocorticoids?
12. When should glucocorticoids be used in combination with other treatments?
13. Which glucocorticoids combinations are preferred?
14. Should glucocorticoids be used in combination with other treatments?

Treatments with biologic DMARDs
15. In patients being considered for treatment with biologic DMARDs, how should an inadequate response to traditional DMARD be evaluated?
16. Which treatments should be ordered prior to starting treatment with biologic DMARDs?
17. Should MTX be coprescribed with biologic DMARDs?
18. When should anti-TNF therapy be used in the treatment of RA?
19. When should abatacept be used in the treatment of RA?
20. When should rituximab be used in the treatment of RA?
21. How should patients be retreated with rituximab?
22. When should tocilizumab be used in the treatment of RA?
23. Which therapeutic strategy is recommended after failure of 1 anti-TNF?
24. Which therapeutic strategy is recommended after failure of 2 anti-TNF?
25. Which therapeutic strategy is recommended after failure of abatacept, rituximab, or tocilizumab?
26. Should therapy be tapered or withdrawn in RA patients who achieve sustained remission?

Supplementary materials including the detailed search strategy, overview and evidence tables, and tools to aid rheumatology healthcare providers in implementing these recommendations will be made available through the CRA website (http://www.adapte.org). Recommendations will be reviewed after the 2-year period to determine if they remain current in the face of emerging evidence.

MATERIALS AND METHODS
Approach to guideline development. De novo guideline development is both time-consuming and costly (funds, expertise, and human resources). The ADAPTE collaboration, an international group of guideline developers and implementers, has developed a systematic framework for adapting guidelines produced for use in one cultural and organizational context to be used in a different cultural and organizational context (see http://www.adapte.org). As there are several RA guidelines published by international rheumatology associations and policy-making organizations, a modified approach based on the ADAPTE framework11,12 was used to systematically identify, appraise, synthesize, and adapt international RA guidelines for use in the Canadian healthcare context.

Assembly of the Canadian RA Working Group. We assembled a nationally representative working group of 16 Canadian RA stakeholders (all are authors) on behalf of the CRA. Representatives from all relevant domains of expertise were sought including clinical (rheumatology and primary care), methodological (epidemiologists/health services researchers/information specialists), rheumatology research trainees, and patient consumers. Rheumatologist experts were representatives of the CRA Therapeutics Committee, key opinion leaders in RA, and/or representatives of regional/local rheumatology associations across the country, from both academic and community settings. Consumer experts had served on multiple RA research projects and decision-making panels and were active members of numerous patient societies including (but not limited to) The Arthritis Society (TAS), the Canadian Arthritis Patient Alliance (CAPA), and the Arthritis Consumer Experts (ACE). Guideline methodology was developed and executed by a central methods team (CMT) made up of 2 rheumatologist experts and research scientists (CB, VB), 2 rheumatology research trainees (GH, PA), and a project coordinator (OS). Following an integrated knowledge translation approach, the full working group (RA experts, patient experts, and primary care and methods experts) were involved in each phase of guideline development by attending working group meetings and/or contributing to e-mail discussions, revising recommendations, participating in consensus voting procedures, and contributing to drafts of the document. No representatives of pharmaceutical companies were involved in any phase of guideline development.

Defining the scope. A comprehensive list of potential key questions was developed after the meeting. Candidate key questions were selected from results of a national needs assessment survey of Canadian rheumatology professionals (n = 164) performed in preparation for guideline development. Additional questions were identified from executive summaries of CRA Therapeutics Committee meetings and published international guidelines. The full working group reviewed the list of candidate questions at a face-to-face meeting and selected 26 priority treatment questions to be addressed by consensus (Table 1).

Search criteria. Included studies were clinical practice guidelines (CPG) and consensus statements (CS) with recommendations for traditional and biologic DMARD currently approved for use in Canada for adult RA populations, and published in English or French between January 2000 and June 2010. Both CPG and CS were included in order to collect the most common prescribed and applied resources used to inform clinical decision-making.
Guidelines that referred to other rheumatic disease populations in addition to RA were included if the major population of interest was RA. Articles were excluded if they were systematic or narrative reviews with recommendations made by a single expert and if they did not address at least one key question posed by the working group. Guidelines were also excluded if they were deemed to be of very poor methodological quality using a validated guideline quality appraisal instrument. All Canadian guidelines were included given their relevance to the Canadian practice setting.

Search strategy. We performed a systematic search for studies according to the inclusion/exclusion criteria detailed above in Medline, Embase, and CINAHL databases combining keyword and major subject headings for: RA, class and specific drug names for traditional DMARD and biologic agents, and guidelines and consensus statements published in English or French between January 2000 and July 2009. In conjunction with the database search, we performed a comprehensive grey literature search of rheumatology societies, guideline clearinghouses, and bibliographic hand searches according to published methods. All search results were screened by 2 independent rheumatology research trainees (GH, PA), and disagreements were resolved by consensus. Search results were updated using the same procedures outlined above to include guidelines published up to and including June 2010. A diagram of search results is presented in Figure 1.

Appraisal of guideline quality. Guideline quality was assessed using a validated questionnaire, the Appraisal of Guidelines Research and Evaluation (AGREE) instrument. The AGREE instrument consists of 23 questions across 6 domains: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence. Domain scores are then used to formulate a single-item overall assessment of the guideline as “Recommend” (R), “Recommend with Provisos” (R*), or “Would Not Recommend” (WNR).

Grading evidence. Systems for assigning levels of evidence differed across guidelines. In order to reconcile these differences we translated each guideline’s grading system onto a custom system for assigning levels of evidence simplified from that developed by the Scottish Intercollegiate Guideline Network (SIGN). A level of evidence and strength of recommendation was assigned for each recommendation according to this custom grading system (Table 2).

Evidence synthesis. Tables of included guidelines containing descriptive characteristics (guideline developer, country, year, topic, target audience, funding sources) and detailed AGREE domain scores were prepared for each subsection of the guideline. Evidence tables containing guideline characteristics (developer and year), recommendations, AGREE summary scores, and supporting evidence were prepared for each key question.

Development of recommendations. For each key question, the full working group was presented with an overview and evidence table summarizing recommendations and supporting evidence from international guidelines. If the panel agreed with at least one existing recommendation, a Canadian recommendation was developed by adapting and rewording existing recommendations. Recent guidelines of high methodological quality were emphasized. Supporting evidence from observational studies and randomized controlled trials (RCT) referenced by the guideline was reviewed in detail. If the panel did not agree with at least one recommendation provided by the guidelines, a recommendation was developed by consensus after considering available evidence cited by relevant guidelines. In special circumstances, additional primary literature identified through supplementary manual literature searches...
Table 2. Custom system for assigning level of evidence and strength of recommendation.

<table>
<thead>
<tr>
<th>Levels of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Strong recommendation:</td>
</tr>
<tr>
<td></td>
<td>• Direct level I evidence</td>
</tr>
<tr>
<td>II</td>
<td>Moderate recommendation:</td>
</tr>
<tr>
<td></td>
<td>• Direct level II evidence or extrapolated level I evidence</td>
</tr>
<tr>
<td>III</td>
<td>Weak recommendation:</td>
</tr>
<tr>
<td></td>
<td>• Direct level III evidence or extrapolated level II evidence</td>
</tr>
<tr>
<td>IV</td>
<td>Consensus recommendation:</td>
</tr>
<tr>
<td></td>
<td>• Expert opinion based on very limited evidence</td>
</tr>
<tr>
<td>NR</td>
<td>Recommendations are not linked to evidence</td>
</tr>
</tbody>
</table>

RCT: randomized controlled trial; NR: not reported.

was sought. Canadian recommendations were worded according to published criteria for improving implementability of guidelines17 and were voted on using a modified Delphi consensus technique. Each participant registered a vote ranging from 1 (disagree strongly with recommendation) to 10 (agree strongly with recommendation), and disagreements were resolved through discussion and multiple rounds of voting accordingly. Extended review. Draft recommendations developed by the working group were sent to members of the CRA for review and comment. Feedback from survey respondents (n = 86) was used to finalize recommendations and inform supporting text discussions. The present document was prepared in accordance with the principles outlined by the AGREE instrument V1 (www.agreecollaboration.org) and the Conference on Guideline Standardization checklist18. These recommendations were then sent for final review by the CRA executive and received official endorsement by the CRA.

RESULTS

Key to Understanding This Guidance

Each recommendation is presented with a level of evidence and strength (Table 2) and is accompanied by supporting text that is structured as follows:

Summary of guidelines. A synthesis of recommendations made by international RA guidelines identified from the systematic review.

Recommendation/supporting evidence. Specific source guidelines that were used for adaptation.

Summary of evidence linked to recommendation. A summary of the original evidence presented in source guidelines used for adaptation.

Evidence to recommendation. A discussion of the guideline panel’s interpretation of the evidence, clinical experience, and values used to develop the recommendation.

Potential barriers for implementation. Canadian system factors that may influence the applicability of the recommendation.

Overarching Principles in the Care of Persons with RA:

1. Patients with RA should be cared for by a rheumatologist or by other healthcare professionals trained and experienced in RA diagnosis, clinical assessment, and appropriate prescription of RA drug therapies;
2. Every Canadian with RA should have timely and equal access to appropriate rheumatologic care;
3. Treatment of patients with RA should be based on shared decision-making between patient and physician. This should include provision of appropriate RA education materials to patients and caregivers and clear discussion of the benefits and potential risks of treatment;
4. The development of shared-care models with primary care physicians and/or other allied health professionals trained in musculoskeletal (MSK) conditions could enhance healthcare delivery for patients with RA, particularly given the current shortage of rheumatologists in Canada. Such models include support for timely identification and referral of early arthritis patients, guidance for monitoring disease activity in patients with established disease, and the management of comorbidities;
5. RA healthcare providers should consider opportunities for engaging patients in research both as participants and as potential research partners/consumer representatives to further the knowledge and understanding of RA.

Recommendations

A summary of these CRA recommendations is presented in Table 3. Algorithms summarizing recommendations for the assessment and treatment of patients with RA are presented in Figure 2 and Figure 3, respectively.

Recommendation 1: The goal of treatment is remission and when not possible, minimal disease activity (I) while controlling symptoms, halting damage, preventing disability, and improving quality of life (IV). (Level I, IV; Strength A)

Summary of guidelines. The search identified 9 clinical practice guidelines (CPG) and 5 consensus statements (CS) that addressed goals of treatment (AGREE rating: Recommend (R) = 7, Recommend with provisos (R*) = 7). Eleven guidelines recommended that the goal should be remission, and when not possible, low disease activity (LDA)19-29, and 2 guidelines recommended a goal of minimal disease activity/LDA20,31. Four guidelines specified additional treatment targets including function, joint destruction, and quality of life outcomes20,28,31,32.

Recommendation/supporting evidence. EULAR 201026 (R), Treat to Target 201025 (R), British Society of Rheumatology (BSR) 200930 (R), SIGN 200032 (R).
**Table 3.** Canadian Rheumatology Association (CRA) recommendation for the pharmacological management of RA with traditional and biologic DMARD.

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Level</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>General RA management strategies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. The goal of treatment is remission and, when not possible, minimal disease</td>
<td>I, IV</td>
<td>A</td>
</tr>
<tr>
<td>activity (I) while controlling symptoms, halting damage, preventing disability, and improving quality of life (IV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. The presence of the following poor prognostic features should be assessed at</td>
<td>II</td>
<td>B</td>
</tr>
<tr>
<td>baseline and considered when making treatment decisions: RF positivity, anti-CCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>positivity, functional limitation, high number of swollen and tender joints,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>early erosions, extraarticular features, high ESR or CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. RA care providers should monitor disease activity as frequently as every 1 to</td>
<td>I, IV</td>
<td>A</td>
</tr>
<tr>
<td>3 months in patients with active RA (I). Patients with well controlled disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and patients in remission can be monitored at longer intervals (IV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Traditional and biologic DMARD therapy should be adjusted every 3–6 months,</td>
<td>I, IV</td>
<td>B</td>
</tr>
<tr>
<td>as long as the goal has not been achieved</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Radiographs of the hands and feet are recommended as frequently as every 6–12</td>
<td>II, IV</td>
<td>B</td>
</tr>
<tr>
<td>months in patients with recent-onset disease (II). Radiographs can be performed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>at longer intervals in patients with established disease (IV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. A change in therapy should be considered in patients with radiographic</td>
<td>IV</td>
<td>D</td>
</tr>
<tr>
<td>progression despite adequate clinical response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment with glucocorticoids</td>
<td>I, IV</td>
<td>A/D</td>
</tr>
<tr>
<td>7. Glucocorticoids (oral, intramuscular, or intraarticular) can be added to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMARD therapy as part of the initial treatment strategy of patients with RA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(I), and may be an option for managing flares, as bridge therapy while waiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for DMARD to take effect, or for symptom control if no other options exist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(IV). Glucocorticoids should be used in the lowest possible dose and tapered as</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rapidly as clinically feasible (IV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment with MTX/DMARD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. In patients with persistent synovitis, DMARD should be introduced as soon as</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>possible</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. MTX is the preferred DMARD with respect to efficacy and safety and should be</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>the first DMARD used in patients with RA unless contraindicated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. A complete blood count (II), liver (I) and renal biochemistry (II), and a</td>
<td>I-IV</td>
<td>B/D</td>
</tr>
<tr>
<td>chest radiograph (II) should be ordered prior to initiating MTX therapy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Dosing of MTX should be individualized to the patient (IV). MTX should be</td>
<td>I, IV</td>
<td>A</td>
</tr>
<tr>
<td>started oral or parenteral and titrated to a usual maximum dose of 25 mg/week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>by rapid dose escalation. In patients with an inadequate response or intolerance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>to oral MTX, parenteral administration should be considered (I)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Initial combination therapy with traditional DMARD should be considered,</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>particularly in patients with poor prognostic features, moderate-high disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>activity, and in patients with recent-onset disease. Combination therapy also</td>
<td></td>
<td></td>
</tr>
<tr>
<td>should be considered in patients who have an inadequate response to monotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. When treating with combination therapy, MTX should be used as the anchor drug</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>unless contraindicated. Combinations not including MTX can be considered on</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a case-by-case basis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Combination therapy with leflunomide and MTX should be used with caution as</td>
<td>I, IV</td>
<td>A</td>
</tr>
<tr>
<td>it is associated with higher toxicity (gastrointestinal and liver) (I) and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>has no added benefit relative to other DMARD combinations (IV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment with biologics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. In patients being considered for biologic therapy, an inadequate response</td>
<td>IV</td>
<td>D</td>
</tr>
<tr>
<td>to DMARD is defined as moderate to high disease activity despite treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with at least 2 DMARD (including MTX unless contraindicated) in mono or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>combination therapy after 3 months at target dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16. Routine laboratory tests (complete blood count, liver and renal biochemistry</td>
<td>IV</td>
<td>D</td>
</tr>
<tr>
<td>and screening for hepatitis B and C (and HIV in high-risk patients) are</td>
<td></td>
<td></td>
</tr>
<tr>
<td>recommended prior to initiating all biologic therapy. Screening for latent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tuberculosis is recommended prior to anti-TNF (particularly early disease),</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>anti-TNF therapy may be an option after failure of DMARD monotherapy or in DMARD naive patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17. MTX coprescription with biologics is recommended for improved efficacy</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>18. Anti-TNF therapy is recommended for treatment of patients with RA after an</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>inadequate response to DMARD (I). In exceptional circumstances involving</td>
<td></td>
<td></td>
</tr>
<tr>
<td>patients with DMARD contraindications or high disease activity and poor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>prognostic factors (particularly early disease), anti-TNF therapy may be an</td>
<td></td>
<td></td>
</tr>
<tr>
<td>option after failure of DMARD monotherapy or in DMARD naive patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. Abatacept is recommended for the treatment of patients with RA after</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>inadequate response to DMARD or anti-TNF therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20. Rituximab is recommended for the treatment of patients with RF-positive RA</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>after an inadequate response to DMARD or anti-TNF therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21. Patients should not be expected to flare before they are retreated with</td>
<td>II, IV</td>
<td>C</td>
</tr>
<tr>
<td>rituximab (IV). Retreatment can occur as early as 6 months if the patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>has had an initial response but has persistent synovitis (II)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22. Tocilizumab is recommended for the treatment of patients with RA after</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>inadequate response to DMARD or anti-TNF therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23. In patients who have failed treatment with 1 anti-TNF due to lack of</td>
<td>I, II</td>
<td>B</td>
</tr>
<tr>
<td>efficacy or toxicity the following options are recommended: switch to another</td>
<td></td>
<td></td>
</tr>
<tr>
<td>anti-TNF (I, II), switch to another biologic with a different mechanism of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>action (abatacept, rituximab, tocilizumab), or add MTX (or other DMARD) if</td>
<td>II/IV</td>
<td>C</td>
</tr>
<tr>
<td>anti-TNF was used in monotherapy (II)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24. In patients who have failed treatment with 2 anti-TNF a switch to another</td>
<td></td>
<td></td>
</tr>
<tr>
<td>biologic with a different mechanism of action (abatacept, rituximab,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tocilizumab) is recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25. In the absence of data on therapeutic strategies after failure of</td>
<td>IV</td>
<td>D</td>
</tr>
<tr>
<td>abatacept, rituximab, or tocilizumab the following options can be considered:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>switch to any biologic not previously tried and failed, add or switch to a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>traditional DMARD not previously tried and failed, or enroll the patient in</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a clinical trial with a new agent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26. If a patient achieves sustained remission after discontinuation of NSAID</td>
<td>IV</td>
<td>D</td>
</tr>
<tr>
<td>and glucocorticoids, a reduction in traditional and biologic DMARD can be</td>
<td></td>
<td></td>
</tr>
<tr>
<td>attempted with caution as a shared decision between the patient and physician</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RA: rheumatoid arthritis; DMARD: disease-modifying antirheumatic drug; anti-CCP: anti-cyclic citrullinated peptide antibody; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HIV: human immunodeficiency virus; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drug; RF: rheumatoid factor.
Summary of evidence linked to recommendation. EULAR 2010 guidelines and the 2010 Treat to Target Taskforce referred to evidence from RCT and several observational studies showing that patients who attain a state of remission have better structural and functional outcomes than patients who have residual disease activity. The 2010 Treat to Target Taskforce qualified, however, that no trial has directly compared targeting remission to other treatment strategies; all strategic trials (studies comparing more intensive treatment strategies to usual care) have used LDA as the threshold to escalate therapy. The 2009 BSR guidelines add that there is evidence from observational studies that remission may be a difficult goal in certain patients. 2000 Scottish guidelines review observational studies emphasizing additional outcomes including symptom control, preventing disability and joint damage, and improving quality of life.

Evidence to recommendation. The guideline panel agreed that remission should be the target but may be difficult in certain patients, particularly those with long-standing RA. Several composite measures of disease activity have been developed and validated in patients with RA. The panel recognizes, however, that composite measures may have limitations in daily routine practice. The panel therefore provides a reference guide of published disease activity criteria/thresholds (Table 4) and agreed that the choice of measure should be left to the discretion of the rheumatologist. Further, the use of patient-centered outcomes (pain, function, quality of life) in addition to disease activity was also emphasized.

Barriers to implementation. None.

Recommendation 2:
The presence of the following poor prognostic features should be assessed at baseline and considered when making treatment decisions: rheumatoid factor (RF) positivity, anticyclic citrullinated peptide antibodies (anti-CCP) positivity, functional limitation, high number
of swollen and tender joints, early erosions, extraarticular features, high erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). (Level II; Strength B)

**Summary of guidelines.** The search identified 7 CPG that addressed prognostic factors (AGREE rating: R = 5, R* = 2). All 7 guidelines identified the following baseline poor prognostic factors: RF and/or anti-CCP positivity, high ESR or CRP levels, early radiographic erosions, and high swollen and tender joint counts. In addition, 3 guidelines included baseline functional disability, 2 included extraarticular disease, 2 included demographic characteristics and disease duration, and 2 included genetic markers, and 1 included grip strength.

**Recommendation/supporting evidence.** 2009 NICE (R), EULAR 2007 (R*).

**Summary of evidence linked to recommendation.** The 2009 NICE guidelines and 2007 EULAR guidelines review observational studies and indirect evidence fromRCT supporting the prognostic value of each factor for clinical and radiographic outcomes in patients with recent-onset RA. 2010 EULAR guidelines state that the titer of anti-CCP and RF is important, but no threshold levels for RF/anti-CCP titers or ESR/CRP values were listed in any of the guidelines. 2009 NICE guidelines also added that there is some evidence that patients who are both RF and anti-CCP positive may have a worse prognosis than patients positive for either antibody alone.

**Evidence to recommendation.** The baseline poor prognostic factors listed in the recommendation are supported by evidence and were agreed to be the most relevant and practical indicators for making treatment decisions. The panel also acknowledged that additional factors influencing prognosis (e.g., comorbidities, sociodemographic, psychosocial, and genetic factors) may also affect treatment decisions.

**Barriers to implementation.** Anti-CCP testing is not uniformly reimbursed by government-funded healthcare across Canada.

**Recommendation 3:** RA care providers should monitor disease activity as frequently as every 1 to 3 months in patients with active RA (I). Patients with well controlled disease and patients in remission can be monitored at longer intervals (IV). (Level I, IV; Strength A)

**Summary of guidelines.** The search identified 12 CPG and 3 CS that addressed frequency of monitoring disease activity (AGREE rating: R = 7, R* = 7, WNR = 1). Seven general RA management guidelines recommended assessments every 1–3 months in active disease, with 5 specifying longer intervals for patients with well controlled disease. One guideline recommended shared-care for patients with well controlled disease by a general practitioner every 3–6 months and by a specialist every 6–12 months.

### Table 4. Reference guide of rheumatoid arthritis disease activity measures

<table>
<thead>
<tr>
<th>Disease Activity Measures</th>
<th>Remission</th>
<th>Low</th>
<th>Moderate</th>
<th>High</th>
<th>Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR/EULAR Boolean-based definition for remission</td>
<td>TJC28 ≤ 1, SJC28 ≤ 1, CRP ≤ 1 mg/dl, PGA ≤ 1</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Each criterion must be satisfied</td>
</tr>
<tr>
<td>ACR/EULAR index-based definition for remission: Simple Disease Activity Index (SDAI)</td>
<td>≤ 3.3</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Disease Activity Score (DAS, range 0–10)</td>
<td>&lt; 1.6</td>
<td>1.6 to 2.4</td>
<td>&gt; 2.4 to 3.6</td>
<td>&gt; 3.6</td>
<td>See details for SDAI below</td>
</tr>
<tr>
<td>Disease Activity Score 28 (DAS28, range 0–9.4)††</td>
<td>&lt; 2.6</td>
<td>2.6 to 3.2</td>
<td>&gt; 3.2 to 5.1</td>
<td>&gt; 5.1</td>
<td>—</td>
</tr>
<tr>
<td>Simplified Disease Activity Index (SDAI, range 0.1–86)</td>
<td>≤ 3.3</td>
<td>&gt; 3.3 to 11</td>
<td>&gt; 11 to 26</td>
<td>&gt; 26</td>
<td>—</td>
</tr>
<tr>
<td>Clinical Disease Activity Index (CDAI, range 0–76)</td>
<td>≤ 2.8</td>
<td>&gt; 2.8 to 10</td>
<td>&gt; 10 to 22</td>
<td>&gt; 22</td>
<td>—</td>
</tr>
<tr>
<td>Patient-reported Rheumatoid Arthritis Disease Activity Index (RADAI, range 0–10); data are medians</td>
<td>—</td>
<td>&lt; 2.2</td>
<td>2.2 to 4.9</td>
<td>&gt; 4.9</td>
<td>—</td>
</tr>
<tr>
<td>Patient Activity Scale (PAS or PASII, range 0–10)</td>
<td>—</td>
<td>≤ 1.9</td>
<td>&gt; 1.9 to 5.3</td>
<td>&gt; 5.3</td>
<td>—</td>
</tr>
<tr>
<td>Routine Assessment Patient Index Data (RAPID3, range 0–30) ≤ 3</td>
<td>3 to 6</td>
<td>&gt; 6 to 12</td>
<td>&gt; 12</td>
<td>—</td>
<td></td>
</tr>
</tbody>
</table>


### Disease Activity Measures

- **DAS28:** Disease Activity Score based on 28-joint counts.
- **TJC28:** Tender joint count based on 28-joint count.
- **SJC28:** Swollen joint count based on 28-joint count.
- **ESR:** Erythrocyte sedimentation rate.
- **CRP:** C-reactive protein, mg/l.
- **PGA:** Patient global assessment of disease activity (VAS 0–10 cm).
- **PhGA:** Physician global assessment of disease activity (VAS 0–10 cm).
- **HAQ:** Health Assessment Questionnaire.
- **MDHAQ:** Multidimensional Health Assessment Questionnaire.
- **DAS:** Disease Activity Score based on 28-joint count (AGREE rating: R = 3, R* = 3).
- **SDAI:** Simplified Disease Activity Index (AGREE rating: R = 3, R* = 3).
- **CDAI:** Clinical Disease Activity Index (AGREE rating: R = 3, R* = 3).

### Evidence to Recommendation

- **Remission:** TJC28 ≤ 1, SJC28 ≤ 1, CRP ≤ 1 mg/dl, PGA ≤ 1.
- **Low:** 1.6 to 2.4.
- **Moderate:** > 2.4 to 3.6.
- **High:** > 3.6.
- **Formula:** [0.54*In(ESR)] + [0.065*4SJC] + [0.33*In(ESR)] + [0.0072*GH] + [0.0072*GH]
- **GH:** Ritchie Articular Index.
- **ESR:** Erythrocyte sedimentation rate.
- **CRP:** C-reactive protein, mg/l.
- **TJC:** Tender joint count.
- **SJC:** Swollen joint count.
- **ESR:** Erythrocyte sedimentation rate.
- **CRP:** C-reactive protein, mg/l.

### Summary of Guidelines

Seven general RA guidelines identified the following baseline poor prognostic factors: RF and/or anti-CCP positivity, high ESR or CRP levels, early radiographic erosions, and high swollen and tender joint counts. In addition, 3 guidelines included baseline functional disability, 2 included extraarticular disease, 2 included demographic characteristics and disease duration, and 2 included genetic markers, and 1 included grip strength.

### Recommendation Supporting Evidence

2009 NICE (R), EULAR 2007 (R*).

### Summary of Evidence Linked to Recommendation

- **ACR/EULAR Boolean-based definition for remission:** TJC28 ≤ 1, SJC28 ≤ 1, CRP ≤ 1 mg/dl, PGA ≤ 1.
- **ACR/EULAR index-based definition for remission:** Simple Disease Activity Index (SDAI) ≤ 3.3, Disease Activity Score (DAS, range 0–10) < 1.6, Disease Activity Score 28 (DAS28, range 0–9.4) < 2.6, Simplified Disease Activity Index (SDAI, range 0.1–86) ≤ 3.3, Clinical Disease Activity Index (CDAI, range 0–76) ≤ 2.8, Patient-reported Rheumatoid Arthritis Disease Activity Index (RADAI, range 0–10); data are medians.

### Evidence to Recommendation

- **Remission:** TJC28 ≤ 1, SJC28 ≤ 1, CRP ≤ 1 mg/dl, PGA ≤ 1.
- **Low:** 1.6 to 2.4.
- **Moderate:** > 2.4 to 3.6.
- **High:** > 3.6.
- **Formula:** [0.54*In(ESR)] + [0.065*4SJC] + [0.33*In(ESR)] + [0.0072*GH] + [0.0072*GH]
- **GH:** Ritchie Articular Index.
- **ESR:** Erythrocyte sedimentation rate.
- **CRP:** C-reactive protein, mg/l.
- **TJC:** Tender joint count.
- **SJC:** Swollen joint count.
- **ESR:** Erythrocyte sedimentation rate.
- **CRP:** C-reactive protein, mg/l.

### Summary of Guidelines

Seven general RA guidelines identified the following baseline poor prognostic factors: RF and/or anti-CCP positivity, high ESR or CRP levels, early radiographic erosions, and high swollen and tender joint counts. In addition, 3 guidelines included baseline functional disability, 2 included extraarticular disease, 2 included demographic characteristics and disease duration, and 2 included genetic markers, and 1 included grip strength.

### Recommendation Supporting Evidence

2009 NICE (R), EULAR 2007 (R*).

### Summary of Evidence Linked to Recommendation

The 2009 NICE guidelines and 2007 EULAR guidelines review observational studies and indirect evidence from RCT supporting the prognostic value of each factor for clinical and radiographic outcomes in patients with recent-onset RA. The 2010 EULAR guidelines state that the titer of anti-CCP and RF is important, but no threshold levels for RF/anti-CCP titers or ESR/CRP values were listed in any of the guidelines. The 2009 NICE guidelines also added that there is some evidence that patients who are both RF and anti-CCP positive may have a worse prognosis than patients positive for either antibody alone.
Seven guidelines recommended assessments at least every 3–6 months for patients taking biologics without providing a distinction based on RA disease status.\textsuperscript{24,35,39,40,41,42,43}

**Recommendation/supporting evidence.** EULAR 2010\textsuperscript{26} (R), Smolen 2010\textsuperscript{25} (R).

**Summary of evidence linked to recommendation.** A systematic review of trials on strategy-driven treatment approaches in RA performed to inform the EULAR 2010 guidelines\textsuperscript{44} concluded that intensive treatment strategies produce a better clinical outcome, improved physical function, and less structural damage than less intensive strategies. The 13 RCT that compared target-driven treatment approaches to usual care used followup intervals of between 1 and 4 months in the treatment group. Two of these RCT\textsuperscript{45,46} showed improved outcomes with monthly assessments and treatment adjustment to a target of LDA compared to assessments every 3 months with treatment adjustment left to the discretion of the rheumatologist. An additional trial showed benefit with monthly assessments and a target-driven treatment approach to routine care with no specified interval for assessment.\textsuperscript{47} The 2010 Treat to Target Taskforce\textsuperscript{25} also provided evidence from observational studies that radiographic progression can be seen in patients with high disease activity in as little as a few weeks. For patients with established disease, a French guideline\textsuperscript{38} provided evidence from prospective cohorts showing that patient-initiated followup was equivalent to physician-scheduled appointments over 6 years.\textsuperscript{48,49}

**Evidence to recommendation.** The panel agreed that frequent assessments with appropriate treatment adjustment in patients with active RA are associated with improved outcomes. The panel also recognized that while 1 month is too short to see a maximal therapeutic effect of DMARD therapy, modifying the treatment approach (dosage change and/or adding short-term glucocorticoid) may be appropriate within this time-
frame. Longer assessment intervals were agreed to be appropriate in patients with well controlled disease, who should be instructed to consult their rheumatologist in case of flare/worsening. Shared-care models with other healthcare providers trained in the assessment of patients with RA could aid in the optimal monitoring of disease activity and adjustment of therapy.

**Barriers to implementation.** There is a shortage of rheumatologists and other healthcare providers trained in the assessment of patients with RA in Canada. Shared-care models are not currently widely available in Canada.

**Recommendation 4:**
Traditional and biologic DMARD therapy should be adjusted every 3–6 months, as long as the goal has not been achieved (Level I, IV; Strength B).

**Summary of guidelines.** One CPG and 1 CS provided general strategies for adjusting traditional and biologic DMARD (AGREE rating: R = 2). Both recommended adjusting therapy until the treatment target is reached. EULAR 2010 guidelines26 suggested adjusting therapy every 1–3 months, although major adjustments in therapy (switching or adding a DMARD or biologic) should occur every 3–6 months, as outlined by their provided algorithm. The Treat to Target Taskforce25 recommended an adjustment in therapy at least every 3 months.

**Recommendation/supporting evidence.** EULAR 201026 (R).

**Summary of evidence linked to recommendation.** EULAR 2010 guidelines26 referred to strategic trials showing that frequent therapy adjustment based on reaching a target response is associated with better outcomes. Timing of adjustment, however, should also consider the pharmacokinetics of the medications used. 2008 BSR guidelines50 suggested that on average 3 months is sufficient to assess the therapeutic effect for the majority of DMARD (except intramuscular gold: 4–6 months47 and hydroxychloroquine: 4 months29). French guidelines suggest that a response to anti-TNF can be assessed after 3 months41,42, and tocilizumab after 3–6 months24.

**Evidence to recommendation.** The panel considered the evidence from strategy-driven RCT and agreed that 3–6 months balances minimizing missed opportunities for timely adjustment with the time needed to observe a therapeutic effect of most treatments. Adjustment in the context of this recommendation refers to changing DMARD strategy (adding or switching agent). Modifying the treatment approach (dosage change and/or adding short-term steroid) can occur more frequently based on the patient’s clinical status (Recommendation 3).

**Barriers to implementation.** There is a shortage of rheumatologists and other healthcare providers trained in the assessment of patients with RA in Canada.

**Recommendation 5:**
Radiographs of the hands and feet are recommended as frequently as every 6–12 months in patients with recent-onset disease (II). Radiographs can be performed at longer intervals in patients with established disease (IV). (Level II, IV; Strength B)

**Summary of guidelines.** The search identified 6 CPG and 3 CS that addressed this question (AGREE rating: R = 2, R* = 7). Two guidelines recommended radiographs every 6–12 months for the first few years of disease22,33, and 7 guidelines recommended annual radiographs without further specification20,24,25,27,31,39,42.

**Recommendation/supporting evidence.** EULAR 200733 (R*).

**Summary of evidence linked to recommendation.** 2007 EULAR33 guidelines reported that the greatest change in radiographic progression occurs within the first 2 years of disease onset and reference observational studies showing that structural progression can be reliably assessed in as little as 6 months using a formal scoring system (progression defined as ≥ 4 Sharp points).

**Evidence to recommendation.** The panel agreed that radiographs should be ordered more frequently in recent-onset disease than in patients with established disease, particularly in patients with poor prognostic factors. The panel also recognized that the timing interval was controversial and depends on the sensitivity to change of the method used for radiograph interpretation and the potential influence of the results on the patient’s therapy. Given that formal radiographic scoring is not performed in routine practice, radiographs every 6 months may not be necessary in all patients. However, in certain cases where there is concern that the patient is developing erosions that were not present initially, repeating radiographs early may be warranted to help guide a change in therapy. Other imaging technologies (ultrasound and magnetic resonance imaging) can also be considered.

**Barriers to implementation.** Limitations in the reliability of interpreting serial radiographs.

**Recommendation 6:**
A change in therapy should be considered in patients with radiographic progression despite an adequate clinical response. (Level IV; Strength D)

**Summary of guidelines.** The search identified 3 CPG and 2 CS that addressed this question (AGREE rating: R = 1, R* = 4). Four guidelines27,39,51,52 suggested a change in therapy in patients with radiographic progression despite an adequate clinical response, while one guideline26 cautioned that lag periods in radiographic progression should be taken into account.

**Recommendation/supporting evidence.** EULAR 201026 (R), FSR 200739 (R*).

**Summary of evidence linked to recommendation.** EULAR
2010 guidelines\textsuperscript{26} and 2007 French guidelines\textsuperscript{39} recommended that radiographic progression should be considered when adjusting therapy, especially if joint damage appears to progress markedly despite the achievement of the desired treatment target, but did not provide citable evidence. EULAR 2010 guidelines, however, also referred to indirect evidence from an RCT suggesting that radiographic change lags the achievement of clinical remission\textsuperscript{53}. Evidence is lacking on the efficacy of adjusting versus maintaining therapy in patients who have radiographic progression despite achieving a clinical response.

\textit{Evidence to recommendation}. The panel recognized that radiographic progression is an important factor in the decision to adjust therapy, but that treatment decisions should take into account progression within the complete clinical context of the patient.

\textit{Barriers to implementation}. Limitations in the reliability of interpreting serial radiographs.

\begin{itemize}
  \item Recommendation 7:
  Glucocorticoids (GC; oral, intramuscular, or intraarticular) can be added to DMARD therapy as part of the initial treatment strategy of patients with RA (I), and may be an option for managing flares, as bridge therapy while waiting for DMARD to take effect, or for symptom control if no other options exist (IV). GC should be used in the lowest possible dose and tapered as rapidly as clinically feasible (IV). (Level I, IV; Strength A/D)
  \item Summary of guidelines. The search identified 8 CPG and 4 CS that addressed the use of GC in RA (AGREE rating: \( R = 5, R^* = 7 \)). Five guidelines recommended using short-term low-dose GC in patients with early RA\textsuperscript{22,23,26,34,54}, 3 recommended using GC for managing flares\textsuperscript{20,23,34}, 3 as bridge therapy while waiting for DMARD to take effect\textsuperscript{20,22,54}, and 3 for other situations\textsuperscript{28,31,52}. Only 2 guidelines recommended against using GC or stated that their use is controversial\textsuperscript{29,32}.
  \item Recommendation/supporting evidence. EULAR 2010\textsuperscript{26} (R), 2009 NICE\textsuperscript{23} (R).
  \item Summary of evidence linked to recommendation. The strongest evidence supporting a role of GC in patients with RA is as part of initial short-term combination therapy with other DMARD in patients with early RA. A systematic review of RCT informing the EULAR 2010 guidelines\textsuperscript{55} showed benefit of short-term treatment with GC for symptom control and inhibiting radiographic progression when added to DMARD monotherapy or DMARD combination therapy in patients with early RA, but found insufficient evidence to recommend an optimal tapering strategy. For the use of GC in other situations, the 2009 NICE guidelines\textsuperscript{23} highlighted a discordance between strong anecdotal evidence of the benefit of using GC as bridge therapy and for managing flares, and the paucity of research studies. EULAR 2007 glucocorticoid guidelines\textsuperscript{56} state that patients treated with GC should be monitored closely and that the risk of adverse events will depend on the dose and duration of GC used.
  \item Recommendation 8:
  In patients with persistent synovitis, DMARD should be introduced as soon as possible. (Level I; Strength A)
  \item Summary of guidelines. The search identified 5 CPG and 5 CS that addressed starting DMARD therapy (AGREE rating: \( R = 4, R^* = 6 \)). Five guidelines recommended starting DMARD immediately/as soon as possible once the diagnosis is made\textsuperscript{21,22,26,27,29} and 5 recommended starting within 2–4 months of persistent symptoms of RA\textsuperscript{20,23,31,32,57}.
  \item Recommendation/supporting evidence. EULAR 2010\textsuperscript{26} (R), Spanish Society of Rheumatology (SER) 2010\textsuperscript{27} (R*).
  \item Summary of evidence linked to recommendation. EULAR 2010 guidelines\textsuperscript{26} and 2010 Spanish guidelines\textsuperscript{27} referred to evidence from RCT and observational studies showing that delaying DMARD therapy results in worse clinical, functional, and radiographic outcomes. EULAR 2010 guidelines\textsuperscript{26} further suggested that DMARD therapy may be initiated in suspected cases of RA and cited recently published 2010 ACR/EULAR RA classification criteria\textsuperscript{9}, which may assist in early diagnosis.
  \item Evidence to recommendation. The panel agreed that there is conclusive evidence supporting early treatment with DMARD in patients with RA. The diagnosis of early RA can be difficult, and therefore the recommendation refers to patients with persistent synovitis, including patients with a strong suspicion of RA, who do not meet full classification criteria.
  \item Barriers to implementation. Lags in appropriate identification and referral of patients with early RA.
  \item Recommendation 9:
  Methotrexate is the preferred DMARD with respect to efficacy and safety and should be the first DMARD used in patients with RA unless contraindicated. (Level I; Strength A)\end{itemize}
Summary of guidelines. The search identified 7 CPG and 6 CS that addressed which DMARD to use first (AGREE rating: R = 6, R* = 7). Seven guidelines recommended starting with MTX as the first DMARD20,23,26,28,31,58; 2 recommended starting with either methotrexate (MTX) or sulfa-lazine (SSZ)22,32, and 3 recommended starting with either MTX or leflunomide (LEF)27,29,59. Two guidelines recommended that hydroxychloroquine (HCQ) or SSZ could be started first in patients with mild disease22,32. One guideline provided an algorithm to guide the choice of initial therapy36.

Recommendation/supporting evidence. EULAR 201026 (R).

Summary of evidence linked to recommendation. 2010 EULAR guidelines26 provided evidence from RCT and observational studies that MTX is effective in DMARD-naive patients with early moderate to severe RA and that no other traditional DMARD or anti-TNF monotherapies have been shown to be superior to MTX in terms of clinical efficacy. They also referred to a systematic review that supports the beneficial longterm safety profile of MTX60. 2007 Spanish guidelines54 referred to observational evidence that MTX has a lower rate of treatment dropout in the medium to long term as compared to other DMARD.

Evidence to recommendation. The panel agreed that there is sufficient evidence to support MTX as the preferred DMARD in patients with RA based on its efficacy and safety profile. The panel recognized that other DMARD have also been proven to be effective (e.g., LEF, SSZ, HCQ, etc.) and may be considered in certain situations. Examples include patients with contraindications to MTX, patients with mild disease and/or in situations in which MTX use may not be desirable (e.g., a young woman who may become pregnant).

Barriers to implementation. None.

Recommendation 10:
A complete blood cell count (CBC) (II), liver (I) and renal biochemistry (II), and a chest radiograph (II) should be ordered prior to initiating methotrexate (MTX) therapy. Screening for hepatitis B/C should be considered (III), and HIV testing is recommended in high-risk patients (IV). (Level I-IV; Strength B/D)

Summary of guidelines. The search identified 3 CPG and 3 CS addressing investigations for MTX (AGREE rating: R = 2, R* = 4). Five guidelines recommended CBC, liver transaminases, kidney biochemistry, and a recent chest radiograph20,50,54,61,62, and 1 suggested all except chest radiograph36. In addition to the factors above, 4 guidelines also recommended serum albumin50,54,61,62 and 4 recommended hepatitis B/C serology20,36,54,61,62 (2 recommended these in all patients61,62, and 2 only in patients with risk factors20,36). Two guidelines recommended pulmonary function tests in select patients50,61, 2 recommended a liver biopsy in patients with preexisting liver disease54,61, and 1 suggested considering ordering an HIV test, fasting glucose, fasting lipids and pregnancy test62.

Recommendation/supporting evidence. Visser 200962 (R*), Pavy 200661 (R*).

Summary of evidence linked to recommendation. Recommended investigations were based on systematic reviews performed as part of 2 international consensus statements61,62. Ordering liver and renal biochemistry and a chest radiograph is based on observational studies showing that renal failure, decreased albumin, elevated transaminases, and baseline chest radiographic abnormalities are associated with increased toxicity from MTX. Ordering a CBC is based on the increased risk of cytopenias in patients treated with MTX. Ordering hepatitis B/C serology and HIV testing in high-risk patients is based on case reports of hepatitis B/C reactivation while on MTX and expert opinion, respectively.

Evidence to recommendation. The panel chose the specified investigations listed in the recommendation based on the available evidence and clinical experience. Hepatitis B/C and HIV testing was supported by weak evidence and was therefore worded as “should be considered.”

Barriers to implementation. None.

Recommendation 11:
Dosing of methotrexate (MTX) should be individualized to the patient (IV). MTX should be started oral or parenteral and titrated to a usual maximum dose of 25 mg per week by rapid dose escalation. In patients with an inadequate response or intolerance to oral MTX, parenteral administration should be considered (I). (Level I, IV; Strength A)

Summary of guidelines. The search identified 3 CPG and 4 CS that addressed dosing of MTX (AGREE rating: R = 1, R* = 6). Six guidelines recommended a starting dose of 5–10 mg, with a maximum dose of 20–25 mg per week2,27,31,34,50,61, and 1 recommended a starting dose of 10–15 mg with a maximum dose of 20–30 mg per week62. Five guidelines commented on the schedule for dose escalation; 2 recommended escalating by 2.5–5 mg every 2–6 weeks27,50, 1 recommended escalating by 5 mg every 2–4 weeks62; 1 recommended escalating every 6 weeks without specifying the dose increment61, and 1 simply recommended rapid dose escalation22. All guidelines recommend starting with oral (po) MTX and switching to parenteral if there is intolerance or lack of efficacy, poor compliance61, or dose ≥ 15 mg31.

Recommendation/supporting evidence. Visser 200962 (R*).

Summary of evidence linked to recommendation. Visser 200962 referred to evidence from RCT supporting higher starting doses of MTX and rapid dose escalation66,63,64. Two trials compared a higher versus lower starting dose of MTX in patients with RA: 12.5–20 mg/wk vs 5–10 mg/wk65 and 25 mg/wk vs 15 mg/wk64. Both trials showed improved efficacy; 1 trial showed no difference in toxicity63, and the other a trend
toward more gastrointestinal (GI) toxicity. Visser 2009 also referred to evidence from retrospective studies that suggested better efficacy and less GI toxicity with parenteral versus oral MTX, potentially explained by the higher bioavailability of subcutaneous (sc) MTX. A recent post-hoc analysis from an RCT also showed that over half the patients that were switched from oral to sc MTX after intolerance or inefficacy showed clinical improvement.

Evidence to recommendation. The panel agreed with starting with higher doses of MTX (e.g., 15 mg) with rapid dose escalation, including in certain situations starting directly at target dose. No specific schedule was recommended, as the optimal schedule for dose escalation was acknowledged to depend on the clinical context of the patient. Initial therapy with sc MTX (e.g., > 15 mg) or switching to sc administration after failure of oral MTX due to intolerance or inefficacy were recognized as appropriate options. In the latter case, other alternatives such as adding or switching DMARD could also be considered.

Barriers to implementation. None.

Recommendation 12: Initial combination therapy with traditional DMARD should be considered, particularly in patients with poor prognostic features, moderate-high disease activity, and in patients with recent-onset disease. Combination therapy should also be considered in patients who have an inadequate response to monotherapy. (Level I; Strength B)

Summary of guidelines. The search identified 5 CPG and 3 CS that addressed when to use traditional DMARD combination therapy (AGREE rating: R = 4, R* = 3, WNR = 1). Two guidelines recommended starting with combination DMARD in all patients with early active RA; 2 recommended starting with combination therapy in certain situations including high disease activity and in the presence of poor prognostic factors, or after failure of DMARD monotherapy; 3 recommended combination therapy after failure of DMARD monotherapy; and one guideline recommended the use of DMARD monotherapy over combination therapy.

Recommendation/supporting evidence. ACR 200836 (R); 2009 NICE 23 (R); EULAR 201026 (R).

Summary of evidence linked to recommendation. 2008 ACR guidelines reviewed the RCT evidence showing efficacy of various specific DMARD combinations in different clinical situations, such as in patients with moderate-high disease activity and poor prognostic factors. 2009 NICE guidelines performed a systematic review of RCT and observational studies and found that several combination therapies (most of which included GC) were superior to monotherapy for both clinical and radiographic outcomes, and that combination therapy was also very likely to be cost-effective. EULAR 2010 guidelines performed a systematic review of RCT and noted that trials comparing combination therapy to monotherapy often did not include an appropriate control arm (e.g., switching to another DMARD monotherapy) and commonly included higher rates of GC use in the combination arm.

Evidence to recommendation. The panel recognized that different highly rated guidelines came to different conclusions regarding the same literature. The panel agreed that while the body of evidence supporting combination therapy has some limitations, there is sufficient evidence to consider the use of specific DMARD combinations as initial therapy and/or after inadequate response to monotherapy, particularly in the clinical situations highlighted in the recommendation.

Summary of guidelines. The search identified 4 CPG and 2 CS that addressed which combination therapies should be used (AGREE rating: R = 2, R* = 3, WNR = 1). Two guidelines recommended MTX as the anchor drug but did not provide details for specific combinations; 4 guidelines recommended specific combination regimens with most including MTX, potentially explained by the higher bioavailability of parenteral versus oral MTX. A recent post-hoc analysis from an RCT also showed that over half the patients that were initially switched from oral to sc MTX after intolerance or inefficacy were recognized as appropriate options. In the latter case, other alternatives such as adding or switching DMARD could also be considered.

Recommendation 13: When treating with combination therapy, methotrexate (MTX) should be used as the anchor drug unless contraindicated. Combinations not including MTX can be considered on a case-by-case basis. (Level I; Strength A)

Summary of evidence linked to recommendation. 2009 NICE 23 and ACR 200836 provided detailed discussions on the evidence for combination therapy in RA. In most trials, MTX was included as part of the combination therapy, with many individual trials showing increased efficacy for combination therapy over monotherapy. Combination therapies with proven efficacy in at least one RCT include: MTX + sulfasalazine (SSZ), MTX + hydroxychloroquine (HCQ), MTX + HCQ + SSZ, MTX + leflunomide (LEF) (see Recommendation 14 for detailed discussion), MTX + azathioprine (AZA), MTX + cyclosporin A (CsA), MTX + intramuscular (IM) gold, IM gold + HCQ, LEF + SSZ, HCQ + SSZ, CsA + LEF. Detailed descriptions of trials are provided in 2009 NICE, ACR 200836, and Katchamart 2009.

Evidence to recommendation. After reviewing the evidence, the panel agreed that there was sufficient evidence to support the use of MTX as the anchor drug when using combination therapy, although other DMARD combinations may also be considered. Several different combination therapies have been shown to be effective in the treatment of RA, but direct comparative effectiveness data of the different combinations are lacking. The panel therefore agreed it was appropriate to provide a list of combinations supported by evidence and the choice of combination should be left to the discretion of the rheumatologist as a shared decision with the patient, based on individual patient circumstances.
Barriers to implementation. The choice of combination therapy may be influenced by provincial formulary guidelines for accessing a biologic.

Recommendation 14:
Combination therapy with leflunomide (LEF) and methotrexate (MTX) should be used with caution as it is associated with higher toxicity (GI and liver) (I) and has no added benefit relative to other DMARD combinations (IV). (Level I, IV; Strength A)

Summary of guidelines. The search identified 1 CPG and 5 CS that addressed the use of combination therapy with MTX + LEF (AGREE rating: R = 1, R* = 5). All guidelines stated that combination therapy with MTX + LEF is effective in RA patients with high disease activity. Three guidelines, however, also highlighted that the treatment is associated with increased toxicity and should be used with caution or careful monitoring.

Recommendation/supporting evidence. Visser 200962 (R*), ACR 200836 (R).

Summary of evidence linked to recommendation. Visser 200962 and ACR 200836 referred to evidence from an RCT showing better efficacy of combination therapy with leflunomide (LEF) + methotrexate (MTX) compared to MTX + placebo in MTX inadequate responders (MTX-IR) with high disease activity. In the same trial, alanine aminotransferase (ALT) levels were abnormal (> 1.2 times upper limit of normal) in 28/130 (31.5%) patients in the combination arm versus 6/133 (6.8%) in the control arm, although in the majority of patients these normalized without need for a change in dose69. A US Food and Drug Administration black-box warning for LEF and risk of severe liver injury was issued July 13, 2010, based on postmarketing surveillance results of 49 cases of severe liver injury including 14 cases of fatal liver failure (46/49 patients were taking concomitant hepatotoxic medications including MTX70).

Evidence to recommendation. The panel recognized that there is evidence from RCT supporting the efficacy of MTX + LEF in patients with high disease activity with an inadequate response to MTX and that many patients have been successfully treated with this combination without serious adverse events. The panel considered, however, that in general, other combination therapies of proven efficacy would be preferred over LEF + MTX due to increased GI and hepatotoxicity. The panel also recognized that LEF combination therapy is typically considered after an inadequate response to MTX, and that in this situation it is not desirable to withdraw MTX to treat with LEF as this may result in worsening of disease control. If LEF + MTX is used, liver enzymes should be monitored monthly and dose reduction of LEF (to 10 mg), or MTX should be considered. Similarly, clinicians should exercise caution when combining LEF with other drugs that have the potential to cause liver injury.

Barriers to implementation. Several Canadian provincial formularies require patients to fail LEF or combination therapy of MTX + LEF to access a biologic.

Recommendation 15:
In patients being considered for biologic therapy, an inadequate response to DMARD (DMARD-IR) is defined as moderate to high disease activity despite treatment with at least 2 DMARD [including methotrexate (MTX) unless contraindicated] in mono or combination therapy after 3 months at target dose. (Level IV; Strength D)

Summary of guidelines. The search identified 10 CPG and 7 CS that addressed a DMARD-IR (AGREE rating: R = 3, R* = 14). The number of DMARD recommended to have been tried and failed varied between 1-320,26,27,29,39,71, 23,35,40,51,72,73, 74,75, and 334, with 1 guideline not specifying a number19. Recommendations regarding an appropriate duration of a DMARD trial ranged from 3 months19,20,29,39,51,71,74 to 6 months31,34,35,40,72,73 with 4 not specifying. Almost all guidelines mandated MTX to be a part of the initial DMARD trial unless contraindicated.

Recommendation/supporting evidence. 2009 NICE23 (R).

Summary of evidence linked to recommendation. Recommendations from available guidelines were based on expert opinion. 2009 NICE guidelines performed a systematic review of RCT and cost-effectiveness studies to inform their recommendation and found insufficient evidence to conclude whether patients failing initial DMARD therapy should receive another DMARD or proceed directly to biologic therapy.

Evidence to recommendation. The present recommendation was developed based on expert opinion taking into account the Canadian practice setting. Biologics, while proven effective in DMARD inadequate responders (DMARD-IR) and DMARD-naive patients (see Recommendations 19, 20, 22), are associated with higher costs and potential risks for toxicity. Prior treatment with 2 DMARD in mono or combination therapy was chosen to balance the potential opportunity for a response to DMARD therapy with early initiation of a biologic that may be necessary to reach the treatment target. Three months at target dose was agreed to be a sufficient period to observe a therapeutic effect for most DMARD while minimizing delays in treatment adjustment.

Barriers to implementation. Although all Canadian provincial formularies currently require failure of at least 2 DMARD prior to accessing a biologic, many also require failure of an adequate trial of combination therapy (commonly defined as 2–3 months).

Recommendation 16:
Routine laboratory tests (complete blood count, liver and renal biochemistry) and screening for hepatitis B and C (and HIV in high-risk patients) are recommended prior to initiating all biologic therapy. Screening for
latent tuberculosis is recommended prior to anti-TNF, abatacept, and tocilizumab. Baseline antinuclear antibody (ANA) testing could be considered prior to starting anti-TNF. (Level IV; Strength D)

Summary of guidelines. The search identified 10 CPG and 3 CS addressing investigations prior to initiating biologics (AGREE rating: R = 2, R* = 10, WNR = 1). Ten guidelines recommended a CBC prior to treatment with a biologic. Nine guidelines included recommendations for anti-TNF, 4 of which recommended a baseline ANA and ordering hepatitis B/C (AGREE rating: R = 4, R* = 9). All guidelines recommended prescrib-

Summary of evidence linked to recommendation. EULAR 2010 guidelines performed a systematic review of RCT examining the efficacy of biologic agents licensed for use in RA and concluded that MTX coprescription with biologic agents is associated with improved efficacy. Direct evidence for added efficacy was shown in trials that compared biologic plus MTX to biologic monotherapy (ADA, ETN, golimumab, rituximab, and tocilizumab); trials included for the remaining biologics [infliximab, certolizumab (CTZ), and abatacept (ABAT)] studied efficacy of the biologic in combination with MTX only. DMARD other than MTX have also been used in combination with biologic agents in RCT and observational studies.

Evidence to recommendation. The panel agreed that there was strong evidence to recommend coprescription of MTX with biologic agents. In cases where MTX cannot be used, another DMARD is recommended. If coprescription with MTX or another DMARD is not possible, certain biologic agents may be used in monotherapy. Currently, ETN, ADA, CTZ, ABAT, and tocilizumab are licensed for use as monotherapy in Canada. Patients that have remained in a low disease state taking biologic monotherapy may not need the reintroduction of a DMARD.

Barriers to implementation. None.

Recommendation 17:
Methotrexate (MTX) coprescription with biologics is recommended for improved efficacy. (Level I; Strength A)

Summary of guidelines. The search identified 9 CPG and 4 CS that addressed MTX coprescription with a biologic (AGREE rating: R = 4, R* = 9). All guidelines recommended prescribing biologics with MTX; 8 added that etanercept (ETN)/adalimumab (ADA) can also be used as monotherapy.

Recommendation/supporting evidence. EULAR 2010 (R), Furst 2010 (R*), Fautrel 2007 (R*).

Summary of evidence linked to recommendation. Systematic
reviews performed by EULAR 2010 guidelines and 2010 CADTH guidelines considered all anti-TNF agents [adalimumab (ADA), certolizumab (CTZ), etanercept (ETN), infliximab (IFX), golimumab (GOL)] and trials in both DMARD-IR and MTX-naive patients. There is direct RCT evidence of efficacy for all anti-TNF therapies in patients who have had an inadequate response to MTX. For IFX, ETN, ADA, and GOL, there is also RCT evidence for efficacy in patients who are MTX-naive. Some patients in these trials were also DMARD-naive and all patients had early RA with high baseline disease activity. There were no head-to-head trials comparing anti-TNF.

Evidence to recommendation. The panel agreed that there was strong evidence that anti-TNF therapy is effective after failure of a DMARD or in patients who are MTX (or DMARD) naive. However, the panel also acknowledged that many patients respond well to initial DMARD therapy and considered the implications of using anti-TNF therapy in DMARD-naive patients, including added costs and potential risks. Therefore, the panel agreed that in most circumstances anti-TNF therapy should be used after a DMARD-IR. Anti-TNF therapy was acknowledged as an option in DMARD-naive patients or after failure of DMARD monotherapy in rare situations outlined in the recommendation, consistent with eligibility criteria for biologic trials in MTX-naive patients.

Barriers to implementation. Canadian provincial formularies restrict access to first-line biologic therapy.

Recommendation 19: Abatacept is recommended for the treatment of patients with RA after an inadequate response to DMARD or anti-TNF therapy. (Level I; Strength A)

Summary of guidelines. The search identified 6 CPG and 1 CS that addressed indications for abatacept (ABAT) (AGREE ratings: R = 4, R* = 3). Five guidelines recommended that ABAT may be used after an inadequate response or intolerance to either DMARD [including methotrexate (MTX)] or anti-TNF therapy, EULAR 2010, EULAR 2012, and EULAR 2010; however, qualified that current practice would be to use an anti-TNF first, and another guideline recommended ABAT only after failure of anti-TNF therapy. Only one guideline, NICE 2008, did not recommend ABAT. No guidelines provided situations in which ABAT may be preferred to other biologics.

Recommendation/supporting evidence. EULAR 2010, CADTH1 (R).

Summary of evidence linked to recommendation. Systematic reviews of RCT used to inform the EULAR 2010 guidelines and 2010 CADTH guidelines provided direct RCT evidence supporting the efficacy of ABAT + MTX in patients with an inadequate response to MTX, and for ABAT + another DMARD in patients with inadequate response to anti-TNF therapy. The review also found RCT evidence for the efficacy of ABAT + MTX versus MTX monotherapy in patients who are DMARD-naive with high disease activity and poor prognostic factors.

Evidence to recommendation. The panel concluded that there was strong evidence that ABAT is effective after failure of DMARD or anti-TNF therapy. The panel also considered that there is evidence for the efficacy of ABAT in DMARD-naive patients, but agreed that, in the rare situations where a biological is being considered as first-line therapy, an anti-TNF would be used.

Barriers to implementation. None.

Recommendation 20: Rituximab is recommended for the treatment of patients with RF-positive RA after an inadequate response to DMARD or anti-TNF therapy. (Level I; Strength A)

Summary of guidelines. The search identified 7 CPG and 3 CS that addressed indications for rituximab (RTX) (AGREE ratings: R = 5, R* = 5). Four guidelines recommended that RTX may be used after an inadequate response or intolerance to either DMARD (including MTX) or anti-TNF therapy, although one suggests that RF-negative patients should still be considered for RTX treatment.

Summary of evidence linked to recommendation. A systematic review of RCT used to inform the EULAR 2010 guidelines provided direct RCT evidence supporting the efficacy of RTX + MTX in patients with an inadequate response to MTX or other DMARD, and patients with an inadequate response to anti-TNF therapy. Smolen 2007 highlighted that the efficacy of RTX relates to RF-positive patients, although one suggests that RF-negative patients should still be considered for RTX treatment. Smolen 2007 highlighted that the efficacy of RTX in RF-negative patients is inconclusive due to limited data from small numbers of RF-negative patients. CADTH 2010 in their systematic review of RCT referenced the same RCT evidence supporting the efficacy of RTX in DMARD-IR patients; however, the review did not consider RTX as an option in DMARD-IR patients due to current Health Canada restrictions on use of RTX only after failure of an anti-TNF.

Evidence to recommendation. The panel agreed that there was strong evidence that RTX is effective after failure of DMARD or anti-TNF therapy in RF-positive patients. The panel also agreed that in certain situations, including patients with a previous history of B cell lymphoma, LTBI, multiple sclerosis, and concomitant vasculitis or overlap syndromes, RTX may be preferred.

Barriers to implementation. Health Canada’s current indica-
tions for RTX do not offer the option of accessing RTX in patients who have had an inadequate response to DMARD.

Recommendation 21:
Patients should not be expected to flare before they are retreated with rituximab (RTX). Retreatment can occur as early as 6 months if the patient has had an initial response but has persistent synovitis. (Level II, IV; Strength C)

Summary of guidelines. The search identified 4 CPG and 3 CS that addressed retreatment with RTX (AGREE rating: R = 2, R* = 5). Four guidelines recommended retreatment after relapse or if patients have persistent disease activity, and one guideline recommended retreatment only after relapse. The remaining 2 guidelines did not provide a specific recommendation. In terms of timing, 6 guidelines recommended retreatment no earlier than every 6 months. Furst 2010 noted that some patients have been retreated as early as at 4 months.


Summary of evidence linked to recommendation. Smolen 2007 and Furst 2010 refer to an open-label extension study of RTX retreatment that showed that retreatment can occur in the setting of persistent synovitis. This is in line with the open-label extension study of RTX and consistent with the concept of treating to target (see Recommendation 1).

Barriers to implementation. Most Canadian provincial formularies require patients with an initial response to RTX to experience flare in order to access RTX retreatment.

Recommendation 22:
Tocilizumab is recommended for the treatment of patients with RA after an inadequate response to DMARD or anti-TNF therapy. (Level I; Strength A)

Summary of guidelines. The search identified 5 CPG and 1 CS that addressed this question (AGREE rating: R = 2, R* = 4). Five guidelines recommended that tocilizumab (TCZ) may be used after an inadequate response or intolerance to an adequate trial of an effective DMARD [including methotrexate (MTX)] or anti-TNF therapy. Only one guideline, NICE 2010, recommended that TCZ be used only after an inadequate response or intolerance to anti-TNF therapy and rituximab (RTX). Four guidelines recommended a dose of 8 mg/kg every 4 weeks and 1 stated that 4 mg/kg can be used but was less effective as monotherapy in DMARD-IR77.

Recommendation/supporting evidence. Furst 2010 (R*), EULAR 2010 (R).

Summary of evidence linked to recommendation. A systematic review of RCT used to inform the EULAR 2010 guidelines provided direct RCT evidence supporting the efficacy of TCZ in patients with an inadequate response to MTX or other DMARD, and in patients with an inadequate response to anti-TNF therapy. Furst 2010 highlighted that although 4 mg/kg can be used, TCZ trials showed improved efficacy with 8 mg/kg over 4 mg/kg.

Evidence to recommendation. The panel agreed that there was strong evidence that TCZ is effective after failure of DMARD or anti-TNF therapy.

Barriers to implementation. Currently, Health Canada approval for dosing of TCZ is to start at 4 mg/kg and increase to 8 mg/kg based on clinical response.

Recommendation 23:
In patients who have failed treatment with 1 anti-TNF agent due to lack of efficacy or toxicity the following options are recommended: switch to another anti-TNF agent (I, II); switch to another biologic with a different mechanism of action [abatacept (ABAT), rituximab (RTX), tocilizumab (TCZ)] (I); or add MTX (or other DMARD) if the anti-TNF agent was used in monotherapy (II). (Level I, II; Strength B)

Summary of guidelines. The search identified 5 CPG that directly addressed treatment strategies after failure of an anti-TNF (AGREE rating: R = 2, R* = 3). Four suggested either switching to another mechanism of action or trying a second anti-TNF with no preference, while 1 recommended only switching to another mechanism of action. Three guidelines also included adding methotrexate (MTX) or adjusting traditional DMARD therapy and dose/interval adjustment of infliximab (IFX) as options. Only 1 guideline suggested that adalimumab (ADA) dose/interval adjustment can be considered.


Summary of evidence linked to recommendation. A systematic review of RCT used to inform the EULAR 2010 guidelines provided direct RCT evidence supporting the efficacy of RTX, ABAT, TCZ, and golimumab in patients who have failed 1 anti-TNF. CADTH referred to a health technology assessment performed by NICE on options for treatment with biologic agents after failure of an anti-TNF, which concluded that switching to a different anti-TNF may have some benefit based on observational studies. CADTH 2010 also examined RCT evidence for dose escalation of biologics and found contradictory evidence for IFX (2 trials showing benefit and 1 showing no benefit) and found evidence against dose escalation of etanercept. There was no evidence provided to support...
Evidence to recommendation. The panel agreed that there is sufficient evidence to support the role of a second anti-TNF agent or switching to a biologic with a different mechanism of action in patients who fail to respond to the first anti-TNF. As biologic therapy is generally more effective when given in combination with DMARD, adding MTX (or other DMARD if MTX is contraindicated) to biologic monotherapy could also be considered. However, the panel realizes that this situation should be rare, as DMARD coprescription is recommended for all biologic therapy (see Recommendation 15). Dose/interval adjustment of IFX may be an option; however, evidence is inconclusive. A preference for a particular therapeutic strategy could not be established due to lack of head-to-head trials, therefore the choice should be a shared decision between patient and physician.

Barriers to implementation. None.

Recommendation 24:
In patients who have failed treatment with 2 anti-TNF agents a switch to another biologic with a different mechanism of action [abatacept (ABAT), rituximab (RTX), tocilizumab (TCZ)] is recommended. (Level II/IV; Strength C)

Summary of guidelines. No guideline specifically made a recommendation regarding treatment strategies after failure of 2 anti-TNF. Two guidelines, however, commented that patients who fail to respond to 2 anti-TNF agents are unlikely to respond to a third.

Recommendation/supporting evidence. SER 201027 (R*).

Evidence to recommendation. The panel recognized that there was no direct evidence comparing different therapeutic strategies in patients who have failed the first anti-TNF19,27,39. Evidence extrapolated from RCT and observational studies, the evidence to recommendation, and the panel agreed that switching to a different mechanism of action [abatacept (ABAT), rituximab (RTX), tocilizumab (TCZ)], the following options can be considered: switch to any biologic not previously tried and failed, add/switch to a traditional DMARD not previously tried and failed, or enroll the patient in a clinical trial with a new agent. (Level IV; Strength D)

Summary of guidelines. No guideline specifically addressed this question. EULAR 2010 provides a treatment algorithm for patients with RA in which patients who fail ABAT, TCZ, RTX, or anti-TNF therapy may be treated with a biologic agent with a different mechanism of action26.

Recommendation/supporting evidence. This recommendation was generated based on consensus of the expert panel.

Evidence to recommendation. In view of the lack of evidence evaluating efficacy of biologic or nonbiologic DMARD in patients with an inadequate response to ABAT, RTX, or TCZ, the panel considered possible strategies with potential benefits including switching the treatment to an agent with a different mechanism of action or to a nonbiologic DMARD, if not previously used. Offering enrollment into a clinical trial is also an option in patients who fail to respond to available therapies, although clinical trials, where appropriate, are an option at any time during the treatment of patients with RA. Lastly, as in any other failure scenario, alternative reasons for failure such as patient nonadherence to treatment (either partial or complete) and alternative diagnoses contributing to patients’ symptoms (e.g., fibromyalgia) should also be explored with the patient and considered when deciding on the appropriate therapeutic strategy.

Barriers to implementation. None.

Recommendation 26:
If a patient achieves sustained remission after discontinuation of NSAID and glucocorticoids, a reduction in biologic and/or nonbiologic DMARD can be attempted with caution as a shared decision between patient and physician. (Level IV; Strength D)

Evidence to recommendation. The search identified 5 CPG and 3 CS that addressed tapering strategies (AGREE rating: R = 3, R* = 5). All guidelines emphasized that there was limited evidence to support specific tapering strategies and/or suggested caution when considering tapering DMARD or biologic therapy.12,25,26,27,39,73,74,77. Two guidelines suggested tapering biologic therapy prior to DMARD26,27, and 1 suggested that tapering either biologic or DMARD therapy can be considered, with no preference for sequencing39.

Recommendation/supporting evidence. EULAR 201026 (R), Furst 201077 (R*).

Summary of evidence linked to recommendation. EULAR 2010 guidelines26 referred to a systematic review on withdrawal of traditional DMARD in patients with established RA
greater than 2 years\textsuperscript{90}. The authors concluded that in patients who achieved remission on DMARD, stopping treatment resulted in significantly more flares compared to patients who continued treatment. However, the pooled analysis included heterogeneous trials of variable quality. The largest trial\textsuperscript{91} in the analysis included 285 patients who were in remission for at least 1 year. Among patients who were randomized to discontinue the DMARD therapy, 38% experienced flare compared to 22% of patients who continued DMARD therapy. A followup study of the same patients showed that achieving remission in the patients who flared was more difficult\textsuperscript{92}. Furst 2010 suggests that biologic therapy may be reduced without loss of effect, but did not provide citable evidence\textsuperscript{77}. No guideline provided a schedule for tapering/withdrawing therapy, although EULAR 2010 suggested that patients should be in remission for at least 12 months before attempting to taper DMARD or biologic therapy based on expert opinion.

Evidence to recommendation. The panel considered that there is currently no validated definition for sustained remission in RA and that there are no appropriately designed RCT comparing tapering strategies for DMARD and biologics. The panel therefore recommended that tapering of either DMARD or biologic therapy could be attempted with caution in sustained remission after successfully discontinuing NSAID and glucocorticoids. There may be a tendency to consider tapering the biologic prior to tapering DMARD based on the added costs of biologic therapy and the limited evidence from small numbers of patients in biologic remission that have discontinued biologic therapy successfully. However, the risk of flare after discontinuing the biologic in patients who failed DMARD due to lack of efficacy should be considered. The decision of whether to taper or withdraw therapy should be made on a case-by-case basis after discussion of the risks and benefits with the patient. Patients should be monitored closely for flares, through either their rheumatologist or family physician. If the patient experiences a flare, they should consult their rheumatologist immediately, and ready access to the rheumatologist should be facilitated to minimize delays in the reinstitution of appropriate therapy.

Barriers to implementation. There may be limited access to timely consultation with a rheumatologist.

DISCUSSION

Five overarching principles and 26 treatment recommendations were developed by a Canadian national multidisciplinary working group based on a synthesis of international guidelines, supporting evidence from observational studies and RCT, and from expert consensus, taking into account the Canadian healthcare context. We anticipate that these recommendations will serve as useful knowledge to support decision-making for rheumatology health professionals and enhance the care of patients with RA. It is understood that there will be specific patient scenarios for which these recommendations may not be applicable and we emphasize that these recommendations should be used with the clinical judgment of the treating physician according to the needs of the patient and the unique clinical circumstance.

These recommendations were developed using a guideline adaptation approach modified from the ADAPTE framework. Developing recommendations through guideline adaptation allowed the working group to maximize efficiency, feasibility, and timeliness of the evidence review and dissemination of Canadian recommendations while using rigorous and systematic methods. Further, we introduced new methodological enhancements including a more sensitive search strategy, a custom grading system to allow harmonization of evidence systems across guidelines, and a new procedure for synthesizing individual recommendations organized according to key question\textsuperscript{12}. This enabled us to develop a comprehensive set of recommendations addressing a large number of a priori treatment questions identified through a national needs assessment survey of Canadian rheumatology professionals\textsuperscript{13}, and to contextualize each newly developed recommendation within all international practice recommendations. Supporting evidence from observational studies as well as RCT linked to each recommendation was reviewed in detail, and potential Canadian healthcare barriers that may affect guideline applicability were highlighted within the discussion of each recommendation to facilitate implementation.

There are limitations to consider when interpreting this guidance. A systematic review of original literature was not performed to inform recommendations, and the possibility that relevant studies were missed cannot be ruled out. These Canadian recommendations, however, were based on a systematic review and quality appraisal of all international practice recommendations published through June 2010, and emphasized recent guidelines of high methodological quality that included systematic reviews and citable evidence. Second, the custom system for assigning levels of evidence was based on study design and did not take into account additional criteria for assessing risk of bias within studies identified by more detailed evidence systems\textsuperscript{93}. The variable evidence systems used by different guideline developers included in the review, however, could not be reconciled by applying a detailed evidence system. Therefore, a simplified system was applied across all guidelines to enable comparability and the original literature linked to each recommendation as well as the Canadian guideline working group’s interpretation of the literature (and, where applicable, other interpretations by different guideline development groups), were discussed in detail in the supporting text of each recommendation.

Future studies that would help inform evidence-based practice include: (a) head-to-head trials examining the comparative effectiveness of treatment with traditional DMARD combinations versus DMARD + biologic, and of the various biologic treatment strategies (including dose escalation) after failure of DMARD, anti-TNF, and newer biologic classes abatacept, rituximab, tocilizumab, respectively; (b) longitudi-
nal studies examining predictors of response to specific drug therapies/drug classes, and of the long-term effects of different DMARD and biologic tapering/withdrawal strategies on clinical and quality of life outcomes; and (c) diagnostic studies comparing the feasibility, reliability, and sensitivity to change of imaging technologies such as ultrasound and magnetic resonance imaging in comparison with traditional radiographs in the assessment of patients with RA.

Conclusion. Recommendations were developed by a Canadian national multidisciplinary working group as a knowledge tool to support decision-making for rheumatology healthcare of persons with RA.

REFERENCES


### Appendix 1. Individual author conflicts of interest.

<table>
<thead>
<tr>
<th>Working Group Member</th>
<th>Involvement in development of guidelines considered in the systematic review</th>
<th>Involvement in endorsement of guidelines considered in the systematic review</th>
<th>Past/current employment by entity having a commercial interest in CDRA guidelines</th>
<th>Past/current employment or consultancy by entity having a commercial interest in CDRA guidelines</th>
<th>Ownership interests (e.g., stocks) in any entity with a commercial interest in CDRA guidelines</th>
<th>Past/current recipient of research funds from any entity with a commercial interest in CDRA guidelines $&gt;10,000</th>
<th>Other potential conflicts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akhavan, Pooreh</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: UCB/CRA/TAS Fellowship Award</td>
<td>Yes: Abbott</td>
</tr>
<tr>
<td>Bombardier, Claire</td>
<td>Yes: Saag 2008, Visser 2009</td>
<td>No</td>
<td>No</td>
<td>Yes: Abbott, Amgen, Biogen Idec, Roche, Merck, Pfizer, Schering, Wyeth</td>
<td>Yes: Abbott, Amgen, Biogen Idec, Roche, UCB, Merck, Pfizer, BMS</td>
<td>Yes: Abbott, Amgen, Bayer, Biogen Idec, Roche, Laktopharm, Merck, Pfizer, Schering, Wyeth</td>
<td>No</td>
</tr>
<tr>
<td>Dooley, Anne</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Harwood, Glen</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: Abbott</td>
</tr>
<tr>
<td>LeClercq, Sharon</td>
<td>Yes: Visser 2009</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: Abbott, Amgen, Wyeth, Roche</td>
</tr>
<tr>
<td>Legare, Jean</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Khairishi, Majed</td>
<td>Yes: Bykerk 2004</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: Abbott, UCB, Amgen, Wyeth, BMS, Roche, Schering, Plough</td>
</tr>
<tr>
<td>Mosher, Diane</td>
<td>Yes: Visser 2009</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: Amgen, Wyeth</td>
<td>Yes: Abbott, Pfizer</td>
<td>Yes: Co-chair of ACAP, which receives money from Abbott, Amgen, Wyeth, Roche, Pfizer, Schering</td>
</tr>
<tr>
<td>Pencharz, James</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Pope, Janet E.</td>
<td>Yes: Visser 2009</td>
<td>No</td>
<td>No</td>
<td>Yes: Abbott, Amgen, BMS, Merck, UCB, Roche, Wyeth, Pfizer, Schering, Actelion, GSK, Medimmune, Mediquest</td>
<td>Yes: Pfizer, BMS, Amgen, Abbott, UCB, Roche, Novartis, Biogen, Celgene, Gencelltech, GSK, Medimmune, Novartis, Mediquest, Medquest</td>
<td>Yes: Pfizer, BMS, Amgen, Abbott, UCB, Roche, Actelion, Medimmune, Merck, GSK</td>
<td>Yes: CDN Rheumatology Research Consortium</td>
</tr>
<tr>
<td>Schier, Ort</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Thomson, John</td>
<td>Yes: Visser 2009</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: Schering</td>
<td>Yes: Schering, Abbott, Amgen</td>
<td>No</td>
</tr>
<tr>
<td>Thorne, Carter</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: Abbott, Amgen, BMS, Schering/Merck, Roche, UCB, Wyeth/Pfizer</td>
<td>Yes: Abbott, Amgen, BMS, UCB, Centofoor, Roche Schering/Merck, Wyeth/Pfizer</td>
<td>Yes: Abbott, Amgen, Roche, Schering/Merck, Wyeth/Pfizer</td>
<td>Yes: 1) CDN Rheumatology Research Consortium 2) Ontario Rheumatology Association 3) Ontario Ministry of Health Drug Programs Branch</td>
</tr>
<tr>
<td>Zummer, Michel</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes: Abbott, Amgen, Roche</td>
<td>Yes: Abbott, UCB, Amgen, BMS, Schering/Merck, Pfizer, Roche</td>
<td>No</td>
</tr>
</tbody>
</table>